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Abstract
A recent focus meeting on Controlling Acute Inflammation was held in London, April 27-28,
2006, organized by D.W. Gilroy and S.D. Brain for the British Pharmacology Society. We
concluded at the meeting that a consensus report was needed that addresses the rapid progress in
this emerging field and details how the specific study of resolution of acute inflammation provides
leads for novel anti-inflammatory therapeutics, as well as defines the terms and key components of
interest in the resolution process within tissues as appreciated today. The inflammatory response
protects the body against infection and injury but can itself become dysregulated with deleterious
consequences to the host. It is now evident that endogenous biochemical pathways activated
during defense reactions can counter-regulate inflammation and promote resolution. Hence,
resolution is an active rather than a passive process, as once believed, which now promises novel
approaches for the treatment of inflammation-associated diseases based on endogenous agonists of
resolution.
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KEY CELL TYPES: THE CELLULAR PLAYERS IN THE STAGE OF
RESOLUTION
In response to injury or infection, specialized, “front-line” leukocytes (polymorphonuclear
neutrophils (PMNs) and eosinophils) migrate to infected/damaged sites to neutralize and
eliminate potentially injurious stimuli. This requirement is perhaps the most obvious but
undeniably critical one for acute inflammation to resolve. Dispensing with the inciting
stimulus will halt further pro-inflammatory mediator synthesis (eicosanoids, chemokines,
cytokines, cell adhesion molecules, etc.) and lead to their catabolism and the curtailment of
pro-inflammatory signaling pathways (Fig. 1). Toll-like receptors are now held to play
essential roles in the recognition of many of these invading organisms (vide infra). This,
coupled with the release of factors that prevent ongoing PMN/eosinophil trafficking and
edema formation, hails the beginning of the end—namely resolution of the acute
inflammatory response and return to normal homeostasis.
One traditional view argued that pro-inflammatory mediator catabolism was sufficient for
inflammation to switch off and the response subsequently just “fizzled out” (1). This is only
part of the process at the tissue level, as PMN or eosinophils if left unchecked could do
untold harm to an already inflamed site and must be disposed of in a controlled and effective
manner. Thus, next in the sequence of events is cell clearance. The exit routes available to
inflammatory leukocytes include systemic recirculation (less well described) or local death
followed by their phagocytosis by recruited monocyte-derived macrophages. Once
phagocytosis is complete, macrophages exit the inflamed site by lymphatic drainage with
evidence that a small population may die locally by apoptosis. If all of these pathways are
strictly followed, then acute inflammation will resolve without causing excessive tissue
damage and give little opportunity for the development of acute, ongoing inflammation and
its associated complications.
The last but equally essential aspect in the quest for tissue resolution and homeostasis is that
the parenchymal/stromal cells that hosted the inflammatory event revert back to a non-
inflammatory phenotype (2). Most current therapies target immune cells in an attempt to
inhibit the production of pro-inflammatory chemical mediators. However, an equally
important target is the active induction of proresolution programs by stromal cells such as
fibroblasts within the inflamed tissues (2).
As with the onset phase of acute inflammation, each of the above steps in the quest for
resolution is also highly coordinated and under the tight control of what may be called
“proresolution” factors (3). These factors and their importance in controlling inflammation
have become apparent only in the past few years (Fig. 1A, B). Here, we discuss the state of
the research in this field as its stands today and highlight the virtues of “resolution” and why
we trust that understanding it in molecular terms may help us in the quest for new drugs to
treat inflammatory diseases.
CHEMICAL MEDIATORS IN RESOLUTION
Indeed, a number of recent reports have heightened the awareness that resolution is an active
process, one that requires activation of endogenous programs that enable the host tissue to
maintain homeostasis (3-5). In this paper, we shall underscore current topics and definitions
of components in resolution as well as outline where gaps in information lie within this new
field. It is apparent that inflammation plays an important role in the pathophysiology of
many common diseases that affect Western civilizations, including some degenerative
diseases not previously thought to have inflammatory components, such as Alzheimer’s and
atherosclerosis. Thus, the cellular mechanisms by which resolution occurs and the key
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biochemical pathways associated (8) with the return to homeostasis/catabasis (return from
disease) clearly open many new avenues for potential therapeutic interventions in a wide
range of diseases associated with unresolved inflammation. These will surely aid in our
understanding of innate immunity and clearance of microbes.
“ANTI-INFLAMMATORY” VS. “PRO-RESOLUTION”
The notion that the inflammatory response generates its own regulators in tandem with the
better-known pro-inflammatory mediators and pathways makes sense teleologically: From
the cybernetic viewpoint it is easier to control a process with both positive and negative
regulatory inputs (Fig. 1B). Or perhaps a finer level of control can be achieved; for example,
consider the car metaphor of hitting the brakes to stop or the accelerator to go. Indeed,
several endogenous regulators of the inflammatory response have already been elucidated
(for reviews, see refs. 3-5), adding support to the idea that this is a widely employed
mechanism. Clearly, disturbances in such counter-regulatory circuits could lead to
exacerbated inflammatory responses just as effectively (although perhaps less obviously)
than excessive activation of the pro-inflammatory cascades (6).
Noteworthy, one of the most widely used classes of anti-inflammatory and
immunosuppressive drugs, the glucocorticoids, have been developed from the pioneering
work of Philip Hench and represents the first successful exploitation of an endogenous anti-
inflammatory mediator, cortisol.
RESOLUTION OF ACUTE INFLAMMATION: WHAT WE KNOW TODAY
Although resolution in cellular and molecular terms has been known to pathologists at the
tissue level for more than 100 years, only recently have we begun to take note. Resolution of
acute inflammation, or its ideal outcome, would be complete resolution. The return to
homeostasis by the tissue was thought to occur by passive mechanisms. Expressly, on
surgical trauma, tissue, or chemical injury, the liberated chemical mediators (exogenous and/
or endogenous) would evoke leukocyte chemotaxis into tissue. The decrease in chemotactic
gradients or “the burning out” of the initial signals was thought to eventually dissipate
depending on the magnitude of the invading microbes and/or injury. Resolution of acute
inflammation via the exodus of neutrophils from tissues after their infiltration and
involvement in host defense, namely, after the job is done, was thought to be a passive series
of events (Fig. 1). The uncovering of several distinct biochemical pathways that are actively
turned on during inflammation in the resolution phase, i.e., when the numbers of neutrophils
infiltrating from the tissues are dropping and are actively pushed back by the mediators
produced (3), provides clear evidence for the role of active biochemical pathways in
resolution.
The resolution phase can be defined at the histological level as the interval from maximum
neutrophilic infiltration to the point when they are lost from the tissue. Concomitantly,
mononuclear cells are then introduced in a nonphlogistic fashion and play a key role in
tissue repair. They, too, are eventually lost from the tissue and are not found in tissue
sections following neutralization of the insult. These cellular terms and temporal
relationships (1, 7) have now called for the need to introduce quantitative indices, which
enable us to define the precise changes in leukocytic traffic and biochemical pathways
activated in exudates, as well as determine the impact of various endogenous mediators,
exogenous compounds, and potential drugs within the resolution phase (8, 9). Along with
these temporal changes in the quantity and quality of the leukocyte infiltrate, additional new
approaches are needed to define how infiltrating cells change the stromal microenvironment
and thereby affect the timing of tissue repair and remodeling (10).
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TOLL-LIKE RECEPTORS, NOD-LIKE RECEPTORS, AND RESOLUTION
The initiation of the inflammatory response during infection or in response to sterile tissue
injury involves two families of receptors, the toll-like receptors (TLRs) and nod-like
receptors (NLRs) (11). TLRs recognize a range of microbial products, the best characterized
is TLR4, which senses lipopolysaccharide (LPS), and TLR2, which senses bacterial
lipoproteins. NLRs also sense bacterial products, the best characterized are NOD1 and
NOD2, which sense peptidoglycan breakdown products, and Nalp3 (also termed cryopyrin),
which is required for caspase-1 activation by several types of bacteria. Nalp3 occurs in an
inflammasome complex with caspase-1, ASC, cardinal, and Nalp2 (12). The activation of
the inflammasome requires TLR priming. TLRs and NLRs also sense products of inflamed
tissue, and notable examples are the sensing of low MW hyaluronic acid fragments by TLR2
and TLR4 (13) and the sensing of uric acid by Nalp3 (14). Uric acid is the causative agent of
gout but is also released by damaged cells, possibly as a general signal for inflammation
(15). All of these represent substantial progress toward understanding innate immunity and
inflammation.
Regarding resolution of inflammation, in the past two years more than 25 inhibitors of TLR
and NLR action have been described, which are all induced by TLRs and therefore act as
negative-feedback inhibitors (16). In effect, TLRs sow the seeds of their own destruction,
and the role of negative regulators clearly indicates how robust the TLR system is. Examples
include splice variants of signaling proteins such as MyD88s, cell surface receptors acting as
decoys such as ST2 and SIGIRR, protein phosphatases such as MKP-1, and proteins such as
Triad3a that promote degradation of TLRs (16). Deletion of genes encoding these proteins
leads to a hyperin-flamed state, as revealed for example by increased infiltration of
neutrophils following LPS challenge in MKP-1 deficient mice (17). Similarly, inhibitors of
NLRs have been found, such as caspase recruitment domain (CARD)-only protein (COP) or
inhibitor of pro-caspase-1 activation (ICEBERG).
Once TLRs or NLRs are triggered, their effects will ultimately be limited, allowing
resolution to proceed. It is also possible that inflammation will become chronic, however, if
the system is somehow dysregulated. An example here is the work of Noble and colleagues,
who have shown that polymeric hyaluronic acid binds TLR2 and TLR4 and generates a
protective signal in the epithelium in lung (13). Fragments of hyaluronic acid, however,
generated in response to tissue injury, become inflammatory, again via TLR2 and TLR4 via
an unknown mechanism. This in turn will lead to the further breakdown of hyaluronic acid
via induction of hyaluronidases, promoting further inflammation. This might turn into a
vicious circle, leading to chronicity, particularly if there is a defect in negative regulation
due to polymorphisms in the negative regulator.
Another example concerns regulatory T cells (T regs) (18, 19). These cells inhibit immunity
and also suppress inflammation. During bacterial infection, TLR2 ligands are sensed by
TLR2 on both T regs and macrophages. The T regs expand but are kept inhibited. TLR2 in
macrophages promotes host defense, which leads to bacterial clearance. Once the TLR2
ligands have been removed, the “brake” is removed from the T regs. They produce IL10,
limit inflammation, presumably promote resolution, and importantly prevent autoimmunity.
These recent results provide insight into the resolution process and how it might become
dysregulated, leading to chronic inflammation.
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HOW TARGETING RESOLUTION RATHER THAN INHIBITING
INFLAMMATION WOULD AFFECT DRUG DISCOVERY PROGRAMS
Current anti-inflammatory therapy arises from our need to control the cardinal signs of
inflammation. Most of the anti-inflammatories studied to date block/antagonize key pro-
inflammatory mediator pathways that are elicited on the initiation of an acute inflammatory
response. Thus, most of the anti-inflammatories in use block key biochemical pathways and/
or block the signaling of key pro-inflammatory mechanisms.
With the past few years has been a growing recognition that, although targeting infiltrating
immune cells can control the inflammatory response, it does not lead to remission or
permanent resolution. Inflammatory reactions occur within distinct micro-environments
composed of tissue-specific cells, such as fibroblasts, endothelial cells, and macrophages,
along with their highly specialized extracellular matrix (ECM) components. Evidence now
exists that such stromal cells can determine the nature and duration of leukocyte infiltrates
(20). At the conclusion of the inflammatory response, stromal cells also contribute to
resolution of inflammation by i) the withdrawal of survival signals, ii) the normalization of
chemokine gradients, and iii) the induction of resolution programs that allow infiltrating
cells to undergo apoptosis or exit the inflamed tissue through draining lymphatics. The
subversion of these pathways would lead to persistent inflammation, which can be
remarkably stable. The relative lack of reagents that target the stromal cells may account for
the failure of current treatments to affect a permanent cure.
Embracing resolution would require a cultural shift in emphasis from depletion therapy to
replacement therapy (i.e., as in endocrinology where a missing agent, e.g., insulin, is
replaced). Currently, anti-inflammatory approaches target chemical mediators generated
during the resolution phase (as defined above, temporally from surrounding tissues or by the
traffic of specific leukocytes, neutrophils, monocytes, and macrophages in and out of the
tissue). Resolution therapies act quite differently in that they serve as activators, e.g.,
receptor agonists, which turn on protective mechanisms that lead to the return of
homeostasis.
Consistently, agonists at receptor targets utilized by endogenous anti-inflammatory
proresolving mediators exert an anti-inflammatory effect when added back into
experimental models/specific settings in the laboratory (4, 5). We envision that new drugs
specifically designed to promote resolving mediators and biochemical pathways will have a
much better compliance and be “homeostatic and modulatory” in their actions, mimicking
the way inflammation naturally subsides in the body. Hence, it is highly likely that these
new proresolving drugs would be better tolerated.
“RESOLUTION TOXIC” AND “RESOLUTION FRIENDLY” DRUGS ALREADY
IN OUR MIDST
It is now very apparent that certain widely used drugs, as well as those in experimental
settings, are “resolution-toxic” in that they derange or impair timely and/or complete
resolution. Since no widely established in vivo models monitored the key components in
resolution, a set of resolution indices were recently introduced to help set benchmarks for
assessing the impact of proresolving agents and their impact within resolution (8). Many
currently used drugs and potential therapeutic compounds without undesirable effects have
slipped by underappreciated.
This is most notable in the case of the inhibition of COX-2 with selective COX-2 inhibitors,
where these inhibitors block the production of PGE2 and PGD2, which play important roles
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in bringing about resolution (21). Their findings also underscore the role of COX-2 and its
products in both the initiation of acute inflammatory response as well as its resolution. Thus,
temporal and spatial positioning of these biochemical pathways can dictate the actions of
their local mediators. Hence, it is important to develop drugs that spare the resolution
process. Besides COX-2 inhibitors, another example may be anti-TNF therapy. It has been
proposed that the poor clinical outcome observed in SIRS patients is related to the
derailment of a proper temporal anti-inflammatory proresolving response.
An ideal drug to treat inflammatory disease would be able to both blunt the inflammatory
response as well as activate the resolution program. Glucocorticoids, in addition to their
anti-inflammatory properties, also promote resolution by stimulating macrophages in a
nonphlogistic proresolving fashion to stimulate the uptake of apoptotic neutrophils (22),
possibly by altering the phenotype of macrophages during their differentiation via a
mechanism involving reorganization of key cytoskeletal elements (23) and/or acting via
another endogenous homeostatic anti-inflammatory factor, annexin 1 (24).
Additionally, the widely used aspirin jump-starts resolution by making up for its loss in
prostaglandin production, which plays key roles in resolution, by instead generating the
epimeric version of lipid mediators (25), such as the aspirin-triggered lipoxins (recently
reviewed in ref. 26), as well as specific epimeric versions of the omega-3 fatty acid-derived
resolvins and protectins. Perhaps these drugs are so widely used today because of a
perceived reduction in the cardinal signs of inflammation and ergo their anti-inflammatory
actions. However, in addition they spare and/or enhance resolution. Thus, it is important for
us to clearly define the earlier signs of resolution in molecular terms, which at present do not
appear to be effectively captured in clinical endpoints. This will be key in appreciating and
selecting the most appropriate anti-inflammatory therapies to use in a given clinical
scenario.
Recent evidence has shown aspirin-triggered lipoxins and glucocorticoid-induced annexin 1
converging onto an identical receptor target, a specific 7-transmem-brane spanning G-
protein coupled receptor (27). Thus, as in the case of pro-inflammatory mediators and the
long list of cascades interlinking them (think of cytokines and chemokines), very recent
work highlights the existence of an anti-inflammatory network, whereby distinct
proresolving mediators and pathways are inter-connected to ensure the correct resolution of
inflammation and return of homeostasis. Besides lipoxins and annexin 1, another example is
that of melanocortins or nuclear receptor agonists and heme oxygenase-1. These endogenous
mediators qualify as agonists of key steps in resolution. Hence, they are proresolving
mediators with anti-inflammatory properties in vivo. It is likely that other drugs in the
general practitioner’s armamentarium would act, at least in part, by promoting or mimicking
proresolution pathways, but this point might have been totally overlooked because it has not
been investigated at all!
Currently no drugs in the clinic are purposefully based on the elicitation of proresolving
pathways, although compounds that target apoptotic pathway may have potential. Recently,
it was shown in a rat carrageenan-induced pleurisy model of resolving inflammation that
manipulation of key signaling pathways influenced resolution (28). In that study, an
inhibitor (PD98059) of MAPK (ERK1/2), administered at the peak of inflammation,
promoted resolution by enhancing inflammatory cell apoptosis. Conversely, administration
of a specific inhibitor (V5) of the proapoptotic Bcl-2 family member, Bax, attenuated
resolution by inhibiting inflammatory cell apoptosis. In another study (29), it was
demonstrated that inhibitors of phosphoinositide-3 kinase, namely wortmannin and
LY294002, administered at the peak of a resolving model of allergic pleurisy in mice
markedly enhanced the clearance of eosinophils by promoting their apoptosis and their
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subsequent removal. However, we would like to stress that if apoptosis is induced
specifically in inflammatory cells, it must be accompanied with efficient macrophage
clearance of the apoptotic cells. If this did not occur, it is likely that failed clearance of the
apoptotic cells would result in secondary necrosis and result in unwanted tissue damage. It
may be that macrophages, or other cells with phagocytic potential (e.g., fibroblasts,
epithelial cells, etc.), have the capacity to deal with induced apoptosis. Fortunately,
macrophage phagocytosis is regarded as a highly efficient and regulatable process and can
therefore be modulated by pharmacological means as occurs with glucocorticoids and
lipoxins (3, 24).
There are, however, drugs that mediate their effects, at least in part, by triggering the
synthesis of endogenous anti-inflammatory mediators, counteracting the activity of early
pro-inflammatory “go signals” to prepare for or facilitate resolution. These include
methotrexate, sulfasalazine, and FK506, which are thought to exert their effects by
increasing adenosine synthesis, another endogenous mediator released very early in the
inflammatory response and acting through the A2A receptor to control leukocyte trafficking
by elevating intracellular levels of cAMP (30). However, glucocorticoids, while acting on
many facets of the inflammatory response, traditionally by curtailing the severity of onset,
may also exert hitherto unknown bona fide proresolution effects through their ability to
hasten apoptosis in certain leukocytes (e.g., eosinophils and lymphocytes) while
concomitantly enhancing the ability of monocyte-derived macrophages to phagocytose
apoptotic cells. One may argue that, given that steroids are used mainly after the
inflammatory event has started, their therapeutic benefits arise largely from eliciting
proresolution pathways.
CLINICAL IMPLICATIONS OF RESOLUTION
What are the clinical implications of nonresolving inflammation? Traditionally, clinicians
have considered certain forms of inflammation nonresolving, as in the case of chronic
Pseudomonas infections experienced in cystic fibrosis, a classic nonresolving inflammation/
infection (1). However, in many clinical conditions infection does not seem to play a role in
the persistence of the disease (i.e., chronic persistent infection is not the same as chronic
persistent inflammation) (7). These include most if not all of the immune-mediated
inflammatory diseases: rheumatoid arthritis, asthma, inflammatory bowel disease, and
psoriasis. In these conditions, the persistence of the inflammatory response appears to have
become divorced from the inciting agent. Classic anti-inflammatory agents only provide
symptomatic relief and do not alter the course of the disease.
It is highly likely that this is because the naturally occurring resolution programs have been
subverted in such diseases. The problem is that current clinical measurements do not
adequately capture or even measure how inflammation differs from repair and resolution (8).
Most clinical parameters take account of disease activity and accumulated damage, but very
few can measure resolution and repair. This finding suggests that we have been using the
wrong measurements and that new clinical and pathological indices will need to be
developed to measure these parameters effectively. It is possible that a number of useful
drugs have been discarded because they did not show efficacy using classic anti-
inflammatory readouts; yet they may have been very effective in promoting resolution.
Thus, the temporal phase of the disease will determine whether a drug is likely to work. For
example, consider that TGF-β is anti-inflammatory during the initial phase of an
inflammatory response yet at the later phases it prolongs inflammation, so that replacement
might be more important than blockade depending on the phase of the disease.
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KINETICS AND THE INVESTIGATOR
An experimental setting at time zero with addition of a pro-inflammatory agonist and/or a
challenge permits us as experimentalists to document precise kinetic events and their
temporal relationships in animal disease models in vivo. It is difficult to capture these
models with isolated cell systems in order to get a handle on the components of resolution
or, for example, determine whether compounds are proresolving (8, 20-24). Moreover, it is
difficult to spot these in clinical situations because patients with active disease do not arrive
in the clinic at time zero. Therefore, it is important to recognize early molecular components
to study them in these individuals for cause-and-effect relationships.
It is becoming increasingly clear that inflammation has a number of tactically placed
checkpoints that limit the magnitude and duration of the response. Defects in these
endogenous anti-inflammatory pathways will arguably predispose the host to chronic
inflammatory diseases (Fig. 1C). Of these endogenous controllers, the cyclooxygenase and
lipoxygenase (LOX) pathways have both protective and pro-inflammatory roles in
inflammation, with the precise function each enzyme plays depending on the inflammatory
stimulus, the phase of the acute inflammatory response when these enzymes are expressed
(31), and whether it is resolving or nonresolving inflammation. This raises a number of
important matters pertaining to anti-inflammatory drug development. We need to be mindful
that during inflammation endogenous pathways may attempt to limit or switch off the
ongoing response. These pathways must not be inadvertently altered by anti-inflammatory
drugs (Fig. 1B, C). The flip-side of this biological scenario is the realization that factors
expressed during resolution could be mimicked and used to push ongoing inflammation
down a proresolution pathway (8, 31). Such an approach would mean developing molecules
that exert multiple effects at various phases of the inflammatory response—limiting
leukocyte trafficking, hastening cell clearance, and helping to restore inflamed stromal tissue
to its prior state. Though a chemist’s nightmare, it could arguably exert striking effects on
ongoing inflammatory diseases. Although we don’t develop drugs along these lines, it is
provocative to think that existing anti-inflammatory agents such as steroids, whose
development was based on an entirely different strategy, may exert potent proresolution
effects arising from their proapoptotic (eosinophils) and prophagocytic properties.
The potential side effect of developing “proresolvers” (and it seems that not all treatments
are without side effects) is that inflammation could be prematurely resolved before it has a
chance to deal with the insulting agent, the very essence of the inflammatory response (26)
in the first instance. This brings us to underlining the fact that all inflammatory responses
are not the same and that developing “pan-inflammatory inhibitors” is not necessarily the
most effective approach to treating inflammation-driven diseases. Thus, we need to foster a
greater understanding of the nature of the response that drives each individual inflammatory
event and its resolution and tailor treatments accordingly. To achieve this goal we must
improve our understanding of the mechanisms in resolution of inflammation and identify
possible approaches to promote this process, perhaps in combination with anti-inflammatory
therapy. Of interest, pharmacological induction of caspase-dependent inflammatory cell
apoptosis by selective cyclin-dependent kinase (CDK) inhibitors can augment the resolution
of established inflammation (32). It was shown that human neutrophils contain functionally
active CDKs (CDK1, 2, and 5) and that different CDK inhibitor drugs induce neutrophil
apoptosis per se and override the retardation of apoptosis induced by survival factor such as
GM-CSF. In addition, the specific CDK inhibitor, R-roscovitine (the anti-cancer agent),
enhanced inflammatory resolution in three in vivo mouse models of established neutrophil-
dependent inflammation (carrageenan-elicited acute pleurisy, bleomycin-induced lung
injury, and passively-induced arthritis). It was also demonstrated that the CDK inhibitor
drug-induced enhanced resolution of established pleurisy was mediated by caspase-
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dependent apoptosis of inflammatory cells. Thus, it is possible that CDK inhibitor drugs
may provide a novel strategy for enhancing the resolution of inflammation and may have
potential for the treatment of inflammatory disorders.
At present, it appears that possible deficiencies in resolution pathways and/or precursors of
proresolving mediators, such as dietary essential omega-3 fatty acids, which are precursors
to resolvins and protectins (Fig. 1C), may lead to prolonged inflammation and the inability
for the tissue to return to homeostasis (26) and complete the full life-cycle per se of the
neutrophils and mononuclear cells recruited to the tissue.
Therefore, it is very likely that the diffused application of unbiased wide-spectrum
approaches (i.e., microarrays, lipid mediator informatics, proteomics) in experimental (8)
and clinical trials will unveil important and “unexpected” links between novel therapeutics
still under development—and likely old drugs, too—and induction of endogenous anti-
inflammatory mediators. We are at the dawn of a new era of drug discovery for
inflammatory diseases, which finally exploit natural endogenous mechanisms operating in
our body to terminate the inflammatory response. The present consensus will hopefully
provide a framework to facilitate our appreciation of these resolution components and their
structure-function that are key to this process for navigating resolution to improve health.
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Figure 1.
Schematic depicting the cellular and molecular components of the inflammatory response
and the requirements for resolution. A) (adapted from Cotran; see ref. 1) depicts the cellular
and histological changes that occur in tissues following an inflammatory insult. Acute
inflammation is characterized by the extravascular accumulation of neutrophils (PMN) and
edema formation early in the response. Later during the response, mononuclear cells and
macrophages accumulate and help prepare the tissue for resolution. B, C) Represent the role
that specific molecular mediators play in these events. In (B), we highlight that early on in
the inflammatory response, immediate and early sequential pre-dominately pro-
inflammatory mediators are released, which initiate and augment the acute-phase of the
response (green lights). However, this is counterbalanced by endogenous anti-inflammatory
signals such as corticosterone, which serve to temper the severity and limit the duration of
the early onset phase. As inflammation progresses, certain “stop signals” at appropriate
“checkpoints” prevent further leukocyte traffic into tissue. These stop signals include the
lipoxins, Resolvins, and prostaglandins (PGs) of the D series and pave the way for monocyte
migration and their differentiation to phagocytosing macrophages, which remove dead cells
and then exit the site of inflammation. Stromal cells such as fibroblasts also contribute to the
resolution of inflammation by the withdrawal of survival signals and the normalization of
chemokine gradients, thereby allowing infiltrating leukocytes to undergo apoptosis or leave
the tissue through the draining lymphatics. This sequential set of responses leads to
complete resolution and, importantly, the restoration of the inflamed tissue to its prior
physiological functioning. This is the ideal sequence of events in physiological
inflammation, which contrast to the situation in pathological inflammation (B) where some
of the factors that initiate the resolution program lead to the inappropriate accumulation of
leukocytes in the wrong place at the wrong time.
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